Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.
December 24, 2009
Submission of the New Drug Application for Pancreatic Enzyme Replacement Therapy Agent SA-001 in Japan
December 18, 2009
Eisai Initiates Procedures to Acquire AkaRx, Inc. in the United States
Eisai Obtains Worldwide Rights to Develop, Market and Manufacture AKR-501, Therapeutic Agent for Thrombocytopenia
December 17, 2009
Eisai Opens New Manufacturing and Process Research Base in India
December 1, 2009
Eisai Launches New Oral Jelly Formulation of Aricept®
World's first oral jelly formulation for Alzheimer's disease treatment
November 25, 2009
FDA Accepts for Review Eisai's NDA for Aricept® 23mg Extended Release Tablets in the United States
November 17, 2009
Eisai Launches Sedative-Hypnotic Agent LUSEDRA™ Injection CIV in the United States
October 30, 2009
GLOBAL PHASE Ⅲ STUDY RESULTS SHOW ERIBULIN MEETS PRIMARY ENDPOINT OF OVERALL SURVIVAL
Eisai Plans to Submit Marketing Authorization Applications for Eribulin Mesylate in Locally Advanced or Metastatic Breast Cancer
October 30, 2009
Eisai and Quintiles Enter into a Strategic Collaboration to Develop Eisai’s Anticancer Compounds
October 28, 2009
Abbott Submits Marketing Authorization Application of Humira® (adalimumab), a Fully Human Monoclonal anti-TNF-α Antibody, for the Treatment of Ankylosing Spondylitis in Japan
October 26, 2009
Eisai and TSD Japan Enter into a License and Joint Development Agreement of Denileukin Diftitox in Japan
October 19, 2009
Eisai Launches “Crystal Veil”- an Allergen Screen Topical Gel
Positively charged gel makes an invisible filter-like screen that provides drug-free protection against airborne allergens such as pollen and house dust
October 16, 2009
Eisai Opens Regional Office in Bahrain
October 1, 2009
Application Submitted for Additional Indications for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors
September 30, 2009
Abbott and Eisai Submit Application for Approval of Humira® (Adalimumab), a Fully Human Monoclonal Anti-TNF-α Antibody, for the Treatment of Crohn's Disease in Japan
September 29, 2009
Eisai and DNDi Enter into a Collaboration and License Agreement to Develop a New Drug for Chagas Disease
September 29, 2009
Eisai Submits Application for Additional Indication of its Proton Pump Inhibitor PARIET® for Non-erosive GERD in Japan
September 29, 2009
KYORIN and Eisai Sign License Agreement for Development and Marketing of Uritos® Tablets in China, India, Sri Lanka and ASEAN Countries
September 25, 2009
Eisai Announces Agreement with Pfizer on Strategic Alliance for Alzheimers Disease Treatment Aricept®
July 31, 2009
Continuation of Policy for Protection of the Company’s Corporate Value and Common Interests of Shareholders
July 28, 2009
Eisai Signs License Agreement with Biocompatibles International for Drug-Eluting Bead Products for Embolisation
July 27, 2009
Eisai Files Submission to Health Authorities in Switzerland for E7389, Novel Anti-cancer Agent, for the Treatment of Metastatic and Locally Advanced Breast Cancer
July 22, 2009
Eisai Receives Approval for a New Oral Jelly Formulation of Aricept® for the Treatment of Alzheimer’s Disease in Japan
July 14, 2009
Eisai Signs License Agreement in Japan for MENILET®, an Oral Osmotic Diuretic and Meniere’s Disease-Improving Agent
July 8, 2009
FDA Accepts sNDA for Alternative Dosing of Dacogen® to Treat Patients with Myelodysplastic Syndromes (MDS)
July 6, 2009
Eisai to Initiate Clinical Trial of Dacogen® in Pediatric Patients with Acute Myelogenous Leukemia in the US
July 6, 2009
Notice on Determination of Details of Stock Options (Stock Acquisition Rights) to be Allotted
July 2, 2009
Current Status of the Development Programs of New Indications and Formulations of Aricept® for Enhancing Patient Value
June 26, 2009
Eisai Establishes “European Knowledge Centre” as its European Strategic Base
Discovery research, clinical development, production, marketing and headquarters operations now housed on one site
June 19, 2009
Notice on Allocation of Stock Options (Stock Acquisition Rights)
June 17, 2009
Eisai Sets Up a Subsidiary in Austria
June 1, 2009
Sanko Junyaku Launches Diagnostic Reagent Kit For Automated Clinical Chemistry Analyser To Determine KL-6, Detecting Marker of Interstitial Pneumonia
May 18, 2009
SymBio Pharmaceuticals Limited and 缅北禁地. Conclude License Agreement for Bendamustine Hydrochloride (SyB L-0501) in Korea and Singapore
May 14, 2009
Notice on New Stock Issuance in the Form of Stock Options
May 9, 2009
Regarding the Statement in Pfizer's 10-Q Report Dated May 8th, 2009
April 28, 2009
Novel Anti-epileptic ZEBINIX® Approved in the European Union
New Option for Treatment of Patients with Partial-Onset Seizures
April 6, 2009
License Agreement for GLIADEL® WAFER in Japan Signed
April 2, 2009
Kissei and Eisai Sign License Agreement for Urief®, A Treatment for Dysuria Associated with Benign Prostatic Hyperplasia for ASEAN Countries, India, and Sri Lanka
March 27, 2009
Notice of Revised Non-consolidated Business Forecast for Fiscal Year Ending March 31, 2009
March 24, 2009
Toyama Chemical and Eisai Decide to Conduct Additional Study for Anti-Rheumatic Drug T-614
March 13, 2009
Approval of Clevudine for the Treatment of Chronic Hepatitis B in the Philippines
February 26, 2009
Eisai and Teikoku Seiyaku Sign Agreements on Transdermal Patch Formulation of Donepezil Hydrochloride
February 26, 2009
Eisai Announces Termination of Joint Development Agreement with Nitto Denko on a Transdermal Patch Formulation of Aricept®
February 23, 2009
Eisai Introduces Nabolin® Felbinac 70 for severe shoulder pain and low back pain
Large-sized high-dose felbinac-containing anti-inflammatory analgesic patch
February 20, 2009
Eisai Signs License Agreement in Europe for an Anti-epileptic Drug
February 10, 2009
Ajinomoto and Eisai Sign Agreement for Distribution of Branched-chain Amino Acid Formula LIVACT® Granules in Asia
February 9, 2009
Eisai Introduces Travelmin® Churop Grape Flavor
The First OTC Motion Sickness Remedy in Drop Type
